Key result
Sintilimab immunotherapy led to a marked reduction in the size of both the primary lung tumor and cardiac metastases in a patient with stage IV lung squamous cell carcinoma.
Why the study?
Cardiac metastases are rare, and the management of cardiac metastases originating from lung cancer remains challenging.
Does sintilimab immunotherapy reduce tumor size in a patient with stage IV lung squamous cell carcinoma and cardiac metastases?
Case Report (n=1)
No
Does sintilimab immunotherapy reduce tumor size in a patient with stage IV lung squamous cell carcinoma and cardiac metastases?
Sintilimab immunotherapy demonstrated efficacy in reducing the size of primary lung squamous cell carcinoma and rare secondary metastases in the left atrium and left ventricle.
No takes yet. Share an insight, caveat, or question.
Cardiac metastases merit consideration in advanced lung cancer; this case leaves open questions on prevalence and detection strategies.
Shen et al. (2024) conducted a case report in Stage IV lung squamous cell carcinoma with cardiac metastases (n=1). Sintilimab was evaluated on Tumor response. Sintilimab immunotherapy led to a marked reduction in the size of both the primary lung tumor and cardiac metastases in a patient with stage IV lung squamous cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: